Skip to main content

Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

Written by Customer Service on . Posted in Public Companies.

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:
Date: May 4, 2022
Time: 2:00-3:00 pm PT (5:00-6:00 pm ET)
Dial In Numbers: 1 (877) 300-8521 (U.S. Toll Free) / 1 (412) 317-6026 (International)

Conference ID: 10166166

Webcast Link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=yOa8KoUv

Replay of the call will be available by visiting the “Events” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.